Target Hemoglobin Level for EPO Therapy in CKD

This publication has 13 references indexed in Scilit:

• Evidence-Based Systematic Literature Review of Hemoglobin/Hematocrit and All-Cause Mortality in Dialysis Patients
  American Journal of Kidney Diseases, 2006
• Association of Achieved Dialysis Dose with Mortality in the Hemodialysis Study
  Journal of the American Society of Nephrology, 2005
• Double-Blind Comparison of Full and Partial Anemia Correction in Incident Hemodialysis Patients without Symptomatic Heart Disease
  Journal of the American Society of Nephrology, 2005
• Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients
  Kidney International, 2004
• Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial
  The Lancet, 2003
• The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients
  Kidney International, 2003
• Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy
  Kidney International, 2000
• The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin
  New England Journal of Medicine, 1998
• The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease
  Published by Elsevier ,1996
• Evidence-based recommendations for the clinical use of recombinant human erythropoietin
  American Journal of Kidney Diseases, 1995